ZBD(SH:603567) Shang Hai Zheng Quan Bao·2025-08-19 19:43Core Viewpoint - The major shareholders of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1][3]. Shareholder Information - As of the announcement date, Bohu Junze Fanglong Equity Investment Center (Limited Partnership) holds 55,792,905 shares, accounting for 5.93% of the total share capital of the company [2]. - Huzhou Saihan Equity Investment Partnership (Limited Partnership) holds 47,098,180 shares, representing 5.01% of the total share capital [2]. Reduction Plan Details - Bohu Junze Fanglong plans to reduce up to 28,229,895 shares, which is no more than 3% of the total share capital, within three months starting from 15 trading days after the announcement. This includes a maximum of 9,409,965 shares through centralized bidding (1% of total share capital) and 18,819,930 shares through block trading (2% of total share capital) [3]. - Huzhou Saihan intends to reduce up to 9,409,965 shares, which is 1% of the total share capital, through centralized bidding within the same timeframe [3]. Shareholder Background - Both Bohu Junze Fanglong and Huzhou Saihan do not have any concerted actions among them [4]. Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [6].